

In the Claims

Please amend the claims as follows. Insertions and deletions in amended claims are indicated by underlining and bracketing, respectively.

1.-11. (Canceled)

12. (Currently amended) A pharmaceutical preparation for a human subject comprising an agent comprising a plurality of human cancer-testis (CT) antigen polypeptides, which, when administered to the human subject, enrich ~~enriches~~ selectively the presence of complexes of ~~an~~ HLA molecules ~~molecule~~ and a plurality of human CT antigen peptides ~~peptide~~, and a pharmaceutically acceptable carrier,
wherein at least one of the human CT antigen polypeptides ~~peptide~~ is ~~a fragment of a human CT antigen~~ encoded by a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO:18 ~~selected from the group consisting of SEQ ID NOs:18, 20 and 22.~~

13. (Canceled)

14. (Currently amended) The pharmaceutical preparation of claim 12, wherein the agent is selected from the group consisting of

- (1) an isolated polypeptides ~~polypeptide~~ comprising the human CT antigen peptide,
- ~~(2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide,~~
- ~~(3) a host cell expressing the isolated polypeptide, and~~
- (4) (2) isolated complexes of the polypeptides ~~polypeptide~~, and an HLA molecules ~~molecule~~.

15. (Currently amended) The pharmaceutical preparation of claim 12 or claim 14 ~~claims 12-14~~, further comprising an adjuvant.

16.-28. (Canceled)

29. (Currently amended) A pharmaceutical composition comprising
an isolated fusion polypeptide comprising at least two different polypeptides, each of the different polypeptides comprising a different human cancer-testis (CT) antigen, wherein one of the at least two different polypeptides is a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO:18 ~~selected from the group consisting of SEQ ID NOs:18, 20 and 22,~~ and

a pharmaceutically acceptable carrier.

30. (Canceled)

31. (Currently amended) The pharmaceutical composition of claim 29 ~~claims 29 or 30,~~ further comprising an adjuvant.

32.-73. (Canceled)

74. (Currently amended) A composition of matter useful in stimulating an immune response to a plurality of human cancer-testis (CT) antigens ~~a proteins comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:19, 21 and 23~~ comprising

a plurality of peptides that are fragments of the human cancer-testis (CT) antigens ~~proteins, one of which antigens comprises an amino acid sequence set forth as SEQ ID NO:19,~~ wherein the peptides bind to one or more MHC molecules presented on the surface of non-testis cells.

75. (Original) The composition of matter of claim 74, wherein at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

76. (Currently amended) The composition of matter of claim 74, wherein at least one of the ~~proteins~~ human cancer-testis (CT) antigens is encoded by a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO:18 ~~selected from the group consisting of SEQ ID NOs:18, 20 and 22.~~

77. (Original) The composition of matter of claim 74, further comprising an adjuvant.

78. (Original) The composition of matter of claim 77, wherein said adjuvant is selected from the group consisting of saponins, GM-CSF, interleukins, and immunostimulatory oligonucleotides.

79.-82. (Canceled)